Changes in Treatment Patterns and Overall Survival in Patients with Early-Stage Non-Small Cell Lung Cancer in the United States after the Incorporation of Stereotactic Ablative Radiation Therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 3, 2018, Pages 259-266

  Haque, Waqar ^a   Szeja, Sean ^b   Tann, Anne ^b   Kalra, Sarathi ^c   Teh, Bin S ^d  

^a Physicians in Medicine Association   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

lung cancer; radiation therapy; stereotactic body radiation therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PROPORTIONAL HAZARDS MODEL; RADIATION ONCOLOGIST; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; UNITED STATES; CANCER REGISTRY; CLINICAL PRACTICE; LUNG TUMOR; MIDDLE AGED; MORTALITY; ONCOLOGY; RADIOSURGERY; TRENDS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; RADIOSURGERY; SEER PROGRAM; UNITED STATES;

EID: 84954443741     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000265     Document Type: Article

References (39)

1. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer V6. 2015. Available at: http://www. nccn. org/professionals/ physician-gls/pdf/prostate. pdf. Accessed May 3, 2015.
2. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Am Thorac Cardiovasc Surg. 2009;15:4-9.
3. Haffty BG, Goldberg NB, Gerstley J, et al. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988;15:69-73.
4. Armstrong JG, Minsky BD. Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. Cancer Treat Rev. 1989;16:247-255.
5. Dosoretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys. 1992;24:3-9.
6. Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1993;27:517-523.
7. Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically inoperable lung carcinoma: The role of radiation therapy. Semin Radiat Oncol. 1996;6:98-104.
8. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149-154.
9. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advancedstage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258-1267.
10. Lavrenkov K, Christian JA, Partridge M, et al. A potential to reduce pulmonary toxicity: The use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. Radiother Oncol. 2007;83:156-162.
11. Keall P. 4-dimenstional computed tomography imaging and treatment planning. Semin Radiat Oncol. 2004;14:81-90.
12. Chang BK, Timmerman RD. Stereotactic body radiation therapy: A comprehensive review. Am J Clin Oncol. 2007;30:637-644.
13. Martin A, Gaya A. Stereotactic body radiotherapy: A review. Clin Oncol (R Coll Radiol). 2010;22:157-172.
14. Uematsu M, Shioda A, Suda A, et al. Computed tomographyguided frameless stereotactc radiotherapy for stage I non-small cell lung cancer: A 5 year experience. Int J Radiat Oncol Biol Phys. 2001;51:666-670.
15. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946-1955.
16. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010-1015.
17. Pan H, Simpson DR, Mell LK, et al. A survey of stereotactic body radiotherapy use in the United States. Cancer. 2011;117: 4566-4572.
18. Surveillance, Epidemiology, and End Results (SEER): About SEER. National Cancer Institute. Available at: http://www. seer. cancer. gov/about. Accessed May 4, 2015.
19. Haasbeek CJ, Palma D, Visser O, et al. Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012; 23:2743-2747.
20. Preston SH, Ho J. National Research Council (US) Panel on Understanding Divergent Trends in Longevity in High-Income Countries. Low life expectancy in the United States: is the health care system at fault. In: Crimmins EM, Preston SH, Cohen B, eds International Differences in Mortality at Older Ages: Dimensions and Sources. Washington, DC: National Academies Press (US); 2010:9. Available at: http://www. ncbi. nlm. nih. gov/books/ NBK62584. Accessed May 8, 2015.
21. Timmerman R, Paulus R, Galvin G, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076.
22. Stephans KL, Djemil T, Reddy CA. Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for Stage I lung cancer in medical inoperable patients. J Thorac Oncol. 2009;4:838-844.
23. Corsco CD, Park HS, Moreno AC, et al. Stage I lung SBRT clinical practice patterns. Am J Clin Oncol. 2014. [Epub ahead of print].
24. Allen MS, Darling GE, Pechett TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013-1019.
25. Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg. 2014;148:2269-2277.
26. Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: A systematic review of the videoassisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg. 2008;86:2016-2018.
27. Grutters JP, Kessels AG, Pils-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons, and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother Oncol. 2010;95:32-40.
28. Palmda D, Lagerwaard F, Rodrigues G, et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys. 2012;82:1149-1156.
29. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomized trials. Lancet Oncol. 2015;16:630-637.
30. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I nonsmall-cell lung cancer: A population-based time-trend analysis. J Clin Oncol. 2010;28:5153-5159.
31. Koshy M, Malik R, Mahmood U, et al. Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I nonsmall cell lung cancer. Radiother Oncol. 2015;114:148-154.
32. Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84:1060-1070.
33. Vest MT, Herrin J, Soulos PR, et al. Use of new treatment modalities for non-small cell lung cancer care in the Medicare population. Chest. 2013;143:429-435.
34. Ling DC, Hess CB, Chen AM, et al. Comparison of toxicity between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2015;15:S1525-S7304. [Epub ahead of print].
35. Chen AB, Li L, Cronin A, et al. Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among Medicare patients with stage III lung cancer. J Thorac Oncol. 2014;9:1788-1795.
36. Hsia TC, Tu CY, Chen HJ, et al. A population-based study of primary chemoradiotherapy in clinical stage III non-small cell lung cancer: intensity-modulated radiotherapy versus 3D conformal radiotherapy. Anticancer Res. 2014;34: 5175-5180.
37. Vogelius IR, Westerly DC, Aznar MC, et al. Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer. Acta Oncol. 2011; 50:772-776.
38. Nichols RC, Huh SN, Henderson RH, et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: A dosimetric study. Clin Lung Cancer. 2011;12:252-257.
39. Walker GV, Giordano SH, Williams M, et al. Muddy water Variation in reporting receipt of breast cancer radiation therapy by population based tumor registries. Int J Radiat Oncol Biol Phys. 2010;76:1285-1288.